Search This Blog

Monday, March 17, 2025

As AI nurses reshape hospital care, human nurses fight back

 The next time you’re due for a medical exam you may get a call from someone like Ana: a friendly voice that can help you prepare for your appointment and answer any pressing questions you might have.

With her calm, warm demeanor, Ana has been trained to put patients at ease — like many nurses across the U.S.

But unlike them, she is also available to chat 24-7, in multiple languages, from Hindi to Haitian Creole.

Ana is also available to chat 24-7, in multiple languages, from Hindi to Haitian Creole.AP

That’s because Ana isn’t human, but an artificial intelligence program created by Hippocratic AI, one of a number of new companies offering ways to automate time-consuming tasks usually performed by nurses and medical assistants.

00:00
04:41

It’s the most visible sign of AI’s inroads into healthcare, where hundreds of hospitals are using increasingly sophisticated computer programs to monitor patients’ vital signs, flag emergency situations and trigger step-by-step action plans for care — jobs that were all previously handled by nurses and other health professionals.

Hospitals say AI is helping their nurses work more efficiently while addressing burnout and understaffing. But nursing unions argue that this poorly understood technology is overriding nurses’ expertise and degrading the quality of care patients receive.

“Hospitals have been waiting for the moment when they have something that appears to have enough legitimacy to replace nurses,” said Michelle Mahon of National Nurses United. “The entire ecosystem is designed to automate, de-skill and ultimately replace caregivers.”

Mahon’s group, the largest nursing union in the U.S., has helped organize more than 20 demonstrations at hospitals across the country, pushing for the right to have a say in how AI can be used — and protection from discipline if they decide to disregard automated advice.

The group raised new alarms in January when Robert F. Kennedy Jr., the incoming health secretary, suggested AI nurses “as good as any doctor” could help deliver care in rural areas. On Friday, Dr. Mehmet Oz, who’s been nominated to oversee Medicare and Medicaid, said he believes AI can “liberate doctors and nurses from all the paperwork.”

Hippocratic AI initially promoted a rate of $9 an hour for its AI assistants, compared with about $40 an hour for a registered nurse. It has since dropped that language, instead touting its services and seeking to assure customers that they have been carefully tested. The company did not grant requests for an interview.

AI in the hospital can generate false alarms and dangerous advice

Hospitals have been experimenting for years with technology designed to improve care and streamline costs, including sensors, microphones and motion-sensing cameras. Now that data is being linked with electronic medical records and analyzed in an effort to predict medical problems and direct nurses’ care — sometimes before they’ve evaluated the patient themselves.

Adam Hart was working in the emergency room at Dignity Health in Henderson, Nevada, when the hospital’s computer system flagged a newly arrived patient for sepsis, a life-threatening reaction to infection. Under the hospital’s protocol, he was supposed to immediately administer a large dose of IV fluids. But after further examination, Hart determined that he was treating a dialysis patient, or someone with kidney failure. Such patients have to be carefully managed to avoid overloading their kidneys with fluid.

Nursing unions argue that this poorly understood technology is overriding nurses’ expertise and degrading the quality of care patients receive.ZUMAPRESS.com

Hart raised his concern with the supervising nurse but was told to just follow the standard protocol. Only after a nearby physician intervened did the patient instead begin to receive a slow infusion of IV fluids.

“You need to keep your thinking cap on — that’s why you’re being paid as a nurse,” Hart said. “Turning over our thought processes to these devices is reckless and dangerous.”

Hart and other nurses say they understand the goal of AI: to make it easier for nurses to monitor multiple patients and quickly respond to problems. But the reality is often a barrage of false alarms, sometimes erroneously flagging basic bodily functions — such as a patient having a bowel movement — as an emergency.

“You’re trying to focus on your work but then you’re getting all these distracting alerts that may or may not mean something,” said Melissa Beebe, a cancer nurse at UC Davis Medical Center in Sacramento. “It’s hard to even tell when it’s accurate and when it’s not because there are so many false alarms.”

Can AI help in the hospital?

Even the most sophisticated technology will miss signs that nurses routinely pick up on, such as facial expressions and odors, notes Michelle Collins, dean of Loyola University’s College of Nursing. But people aren’t perfect either.

“It would be foolish to turn our back on this completely,” Collins said. “We should embrace what it can do to augment our care, but we should also be careful it doesn’t replace the human element.”

A March 2025 image from the website of artificial intelligence company Xoltar shows two of of their demonstration avatars for video calls with patients.AP

More than 100,000 nurses left the workforce during the COVID-19 pandemic, according to one estimate, the biggest staffing drop in 40 years. As the U.S. population ages and nurses retire, the U.S. government estimates there will be more than 190,000 new openings for nurses every year through 2032.

Faced with this trend, hospital administrators see AI filling a vital role: not taking over care, but helping nurses and doctors gather information and communicate with patients.

‘Sometimes they are talking to a human and sometimes they’re not’

At the University of Arkansas Medical Sciences in Little Rock, staffers need to make hundreds of calls every week to prepare patients for surgery. Nurses confirm information about prescriptions, heart conditions and other issues — like sleep apnea — that must be carefully reviewed before anesthesia.

The problem: many patients only answer their phones in the evening, usually between dinner and their children’s bedtime.

Hospital administrators see AI filling a vital role: not taking over care, but helping nurses and doctors gather information and communicate with patients.AFP via Getty Images

“So what we need to do is find a way to call several hundred people in a 120-minute window — but I really don’t want to pay my staff overtime to do so,” said Dr. Joseph Sanford, who oversees the center’s health IT.

Since January, the hospital has used an AI assistant from Qventus to contact patients and health providers, send and receive medical records and summarize their contents for human staffers. Qventus says 115 hospitals are using its technology, which aims to boost hospital earnings through quicker surgical turnarounds, fewer cancellations and reduced burnout.

Each call begins with the program identifying itself as an AI assistant.

“We always want to be fully transparent with our patients that sometimes they are talking to a human and sometimes they’re not,” Sanford said.

While companies like Qventus are providing an administrative service, other AI developers see a bigger role for their technology.

Israeli startup Xoltar specializes in human-like avatars that conduct video calls with patients. The company is working with the Mayo Clinic on an AI assistant that teaches patients cognitive techniques for managing chronic pain. The company is also developing an avatar to help smokers quit. In early testing, patients have spent about 14 minutes talking to the program, which can pick up on facial expressions, body language and other cues, according to Xoltar.

Nursing experts who study AI say such programs may work for people who are relatively healthy and proactive about their care. But that’s not most people in the health system.

“It’s the very sick who are taking up the bulk of healthcare in the U.S. and whether or not chatbots are positioned for those folks is something we really have to consider,” said Roschelle Fritz of the University of California Davis School of Nursing.

https://nypost.com/2025/03/16/health/as-ai-nurses-reshape-hospital-care-human-nurses-are-pushing-back/

Eisai to buy "dementia ecosystem" partner EcoNaviSta

 Eisai's ambition to develop an integrated care system for people with dementia has taken another step forward with a decision to take control of EcoNaviSta, a specialist in software used to provide patient monitoring.

The Japanese pharma company – currently in the process of rolling out new amyloid-targeting Alzheimer's therapy Leqembi (lecanemab) worldwide – has launched a JPY 2,190-per-share tender offer for EcoNaviSta's shares on the Tokyo Stock Exchange, less than a year after partnering with the company.

Shares in EcoNaviSta closed up two-thirds at JPY 2,116 today, and the total purchase price for the company is expected to be approximately JPY 16 billion ($107 million).

EcoNaviSta has developed a software-as-a-service (SaaS) platform for home monitoring systems used in nursing care and has been working with Eisai to harness the technology to pick up changes in cognitive function among residents in care home facilities.

The care home setting is important in Japan as, among the country's rapidly ageing population, a large number of the elderly choose to move into non-assisted living facilities – i.e. those without nursing support – or condominium developments aimed at seniors.

The collaboration has looked at combining Eisai's NouKNOW smart device-based app – which allows people to self-assess their cognitive performance and spot declines that may signal the onset of dementia – alongside EcoNaviSta's Life Rhythm Navi, which generates a health status rating from sleep and lifestyle data, and a patented dementia prediction software platform.

In 2023, Eisai launched a dedicated subsidiary company called Theoria Technologies that is developing a "digital ecosystem" to support people with dementia, built around NouKNOW, and EcoNaviSta's software will add to that effort as a "core solution," said the company. It has also partnered with Tokyo-based Lifenet Insurance Co to develop a series of insurance products specifically for people with dementia and other ageing-related diseases.

"Eisai believes that it will be possible to create pathways that will lead to the encouragement of visits to medical institutions by visualising risks using EcoNaviSta's dementia prediction AI and...NouKNOW for users of Life Rhythm Navi," said the drugmaker.

The hope is that will, in turn, lead to "early examinations, diagnosis, and treatment among sufferers with undiagnosed [mild cognitive impairment] and dementia," it added. At the same time, Eisai hopes to generate real-world data from the platform that can be used to develop new services in dementia and other disorders such as insomnia and epilepsy.

https://pharmaphorum.com/news/eisai-buy-dementia-ecosystem-partner-econavista

Dyne’s Duchenne Exon Skipping Oligomer Shows ‘Differentiated’ Clinical Effect

 

Dyne is eyeing an accelerated approval filing for DYNE-251 in early 2026 that would pit the asset against Sarepta’s Exondys 51 in a patient population amenable to exon 51 skipping.

Dyne Therapeutics’ investigational oligomer therapy DYNE-251 maintained its functional benefits through 18 months of follow-up in patients with Duchenne muscular dystrophy, according to a Sunday release from the company. Dyne remains on track for a regulatory submission in early 2026.

In a Sunday note, BMO Capital Markets analysts wrote that these findings are “supportive” of the asset’s accelerated approval in Duchenne muscular dystrophy (DMD).

The data come from a long-term readout of Dyne’s Phase I/II DELIVER trial, testing the asset in patients who are amenable to exon 51 skipping. This represents about 13% of the DMD population.

The results, which will be presented at the 2025 Clinical & Scientific Conference of the Muscular Dystrophy Association, showed that the 10-mg/kg dose of DYNE-251, given once every four weeks, could maintain multiple functional improvements through 18 months.

Meanwhile, patients treated with the selected registrational dose, once-monthly 20-mg/kg, saw slightly shorter-term functional improvements through 12 months.

DELIVER found DYNE-251 to be tolerable, with no new documented serious adverse events or safety signals of concern.

In a note to investors on Sunday, Stifel analysts said the readout “continues to support a real and differentiated clinical effect for DYNE-251.” The analysts also called out “compelling dystrophin data.”

In its press release on Sunday, Dyne reported that dystrophin expression in patients treated with the registrational dose of DYNE-251 reached 8.72% of normal expression levels, a “high single-digit increase,” according to the Stifel note.

Taken together, DYNE-251’s functional and biomarker data “demonstrate a consistent/sustained treatment benefit and acceptable safety,” the BMO analysts wrote. DYNE-251 could also have a convenience edge over other approved oligomer therapies for DMD, which could help distinguish the treatment in an increasingly crowded space, according to the analysts, who called its once-per-month dosing schedule an “attractive regimen,” in comparison to similar drugs that are taken weekly.

Sarepta Therapeutics’ antisense oligonucleotide Exondys 51 captures around 25% to 40% of the market in the Duchenne patients targeted by Dyne’s molecule, as per the BMO note. With these data, BMO forecasts around a 20% penetration for DYNE-251. Dyne could encounter additional headwinds from Sarepta’s gene therapy Elevidys, which was approved by the FDA in 2023 and according to the analysts could be given to “most” eligible patients by around 2030.

https://www.biospace.com/drug-development/dynes-duchenne-exon-skipping-oligomer-shows-differentiated-clinical-effect